Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation

Thromb Haemost. 2012 Sep;108(3):583-5. doi: 10.1160/TH12-03-0149. Epub 2012 Jul 10.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antithrombins / adverse effects*
  • Antithrombins / pharmacokinetics
  • Antithrombins / therapeutic use
  • Arthroplasty, Replacement
  • Atrial Fibrillation / complications
  • Benzimidazoles / adverse effects*
  • Benzimidazoles / pharmacokinetics
  • Benzimidazoles / therapeutic use
  • Blood Coagulation Factors / therapeutic use
  • Colectomy
  • Combined Modality Therapy
  • Dabigatran
  • Emergencies*
  • Erythrocyte Transfusion
  • Factor VIIa / therapeutic use
  • Fatal Outcome
  • Female
  • Hemostatics / therapeutic use*
  • Humans
  • Kidney Diseases / complications
  • Kidney Diseases / metabolism
  • Male
  • Plasma
  • Postoperative Hemorrhage / chemically induced*
  • Postoperative Hemorrhage / surgery
  • Postoperative Hemorrhage / therapy
  • Recombinant Proteins / therapeutic use
  • Renal Dialysis
  • Resuscitation / methods*
  • Thrombophilia / drug therapy
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacokinetics
  • beta-Alanine / therapeutic use

Substances

  • Antithrombins
  • Benzimidazoles
  • Blood Coagulation Factors
  • Hemostatics
  • Recombinant Proteins
  • beta-Alanine
  • prothrombin complex concentrates
  • recombinant FVIIa
  • Factor VIIa
  • Dabigatran